Arch Biopartners closed a private placement raising CAD $374,000 for general working capital and research.

From GlobeNewswire: 2025-03-14 16:30:37

Arch Biopartners Inc. has successfully closed a private placement offering, raising CAD $374,000 through the sale of 145,000 common shares priced at CAD $1.55 and 90,000 common shares priced at USD $1.15. The proceeds will be used for general working capital and research expenses. The Offering is subject to regulatory approvals and includes finders’ fees totaling CAD $5,425. All Common Shares issued will be subject to a hold period of four months and one day. The Company has 65,856,366 common shares outstanding and is focused on preventing acute kidney injury and organ damage caused by inflammation through its drug candidates LSALT peptide and cilastatin. For more information, visit their website.



Read more at GlobeNewswire: Arch Biopartners Closes Non-Brokered Private Placement